Objective: Compared with those in type 2 diabetes mellitus (T2DM) patients without diabetic peripheral neuropathy (DPN), alterations in brain iron levels in the basal ganglia (an iron-rich region) and motor and cognitive dysfunction in T2DM patients with DPN have not been fully elucidated. We aimed to explore changes in brain iron levels in the basal ganglia in T2DM patients with DPN using quantitative susceptibility mapping (QSM).
Methods: Thirty-four patients with DPN, fifty-five patients with diabetes without DPN (non-DPN, NDPN), and fifty-one healthy controls (HCs) were recruited and underwent cognitive and motor assessments, blood biochemical tests, and brain QSM imaging. One-way ANOVA was applied to evaluate the variations in cognitive, motor and blood biochemical indicators across the three groups. Then, we performed multiple linear regression analysis to identify the possible factors associated with the significant differences in susceptibility values of the basal ganglia subregions between the two T2DM groups.
Results: Susceptibility values in the putamen and the caudate nucleus were greater in the T2DM patients than in the HCs (DPN patients vs. HCs, p < 0.05; NDPN patients vs. HCs, p < 0.05, FDR correction), and there were no significant differences between the DPN patients and NDPN patients. Multiple linear regression analysis revealed that age and history of diabetes played crucialroles in brain iron deposition in the putamen and the caudate nucleus. Notably, DPN in T2DM patients had no effect on brain iron deposition in the putamen or the caudate nucleus. The susceptibility values of the putamen was positively correlated with the Timed Up and Go test score and negatively correlated with gait speed, the Montreal Cognitive Assessment score, and the Symbol Digit Modalities Test score in T2DM patients.
Conclusions: Iron-based susceptibility in the putamen, measured by QSM, can reflect motor function in T2DM patients and might indicate micropathological changes in brain tissue in T2DM patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.brainres.2024.149263 | DOI Listing |
Updates Surg
January 2025
Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
The purpose of this study was to identify whether the preoperative hemoglobin to albumin ratio (HAR) could predict the prognosis of patients who underwent colorectal cancer (CRC) radical resection. This study enrolled 4018 consecutive CRC patients, calculating HAR as the hemoglobin count divided by albumin count. Patients were divided into the high and low HAR groups based on a cut-off value (0.
View Article and Find Full Text PDFAim: To evaluate the efficacy of sesame oil-pulling in periodontitis with/without Type2 Diabetes Mellitus (T2DM), compared to Chlorhexidine, for its oral and systemic health benefits.
Material And Methods: Total of 120 periodontitis patients, without (Group A; 60)/with (Group B; 60) T2DM, underwent control (chlorhexidine 0.12%; Group A1 & B1) and test (sesame oil-pulling; Group A2 & B2) interventions.
Cardiovasc Diagn Ther
December 2024
Department of Cardiology, Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Background: As a novel oral anti-hyperglycemic agent, sodium-glucose cotransporter 2 inhibitors (SGLT2-i) have been demonstrated to improve cardiovascular outcomes in acute myocardial infarction (AMI) patients with type 2 diabetes mellitus (T2DM). However, the mechanism responsible for the beneficial effects remains unclear. Recently, extensive studies have demonstrated a close relationship between elevated fasting triglyceride-glucose (TyG) index and the risk of AMI.
View Article and Find Full Text PDFDiabetes Obes Metab
January 2025
UOSD Diabetologia Endocrinologia, ASL RM5, Rome, Italy.
Aim: This real-world, retrospective cohort study aimed to assess the efficacy, safety and tolerability of oral semaglutide-the first GLP-1 receptor agonist available in oral form-in patients aged 65 years and older with type 2 diabetes mellitus (T2DM).
Materials And Methods: The primary endpoint was the change in glycated haemoglobin (HbA1c) from baseline (V1) to six months (V3). Secondary endpoints included change in body weight, proportion of patients achieving HbA1c <7%, proportion of patients achieving both an HbA1c reduction of ≥1% and a body weight reduction of ≥5%.
J Diabetes
January 2025
Department of Pharmacy, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China.
Objective: Provide an evidence-based basis for the selection of cardiovascular benefit drugs in Type 2 diabetes mellitus (T2DM) patients with cardiovascular disease (CVD).
Methods: Conduct a comprehensive search of all relevant literature from PubMed, Embase, Web of Science, Cochrane Library, and Clinical Trials.gov from their establishment until December 13, 2023, and select randomized controlled trials (RCTs) that meet the pre-established inclusion and exclusion criteria.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!